Abstract
Background: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Patients and methods: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. Conclusions: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 640-642 |
| Number of pages | 3 |
| Journal | Annals of Oncology |
| Volume | 7 |
| Issue number | 6 |
| Publication status | Published - Aug 1996 |
Fingerprint
Keywords
- Advanced salivary gland carcinoma
- CAP regimen
- Chemotherapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. / Licitra, L.; Cavina, R.; Grandi, C.; Di Palma, S.; Guzzo, M.; Demicheli, R.; Molinari, R.
In: Annals of Oncology, Vol. 7, No. 6, 08.1996, p. 640-642.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients
AU - Licitra, L.
AU - Cavina, R.
AU - Grandi, C.
AU - Di Palma, S.
AU - Guzzo, M.
AU - Demicheli, R.
AU - Molinari, R.
PY - 1996/8
Y1 - 1996/8
N2 - Background: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Patients and methods: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. Conclusions: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.
AB - Background: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. Patients and methods: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. Conclusions: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.
KW - Advanced salivary gland carcinoma
KW - CAP regimen
KW - Chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=0029792962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029792962&partnerID=8YFLogxK
M3 - Article
C2 - 8879381
AN - SCOPUS:0029792962
VL - 7
SP - 640
EP - 642
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 6
ER -